MAP2K7 and melanoma: Dabrafenib/trametinib treatment helps melanoma cells escape from the microenvironment, which may be a predictor of the effectiveness of dual BRAF/MEK (mitogen-activated protein kinase kinase) inhibitors in treating melanoma (28).